Lexicon Pharmaceuticals (LXRX) Non Operating Investment Income (2010 - 2022)
Lexicon Pharmaceuticals (LXRX) posted quarterly Non Operating Investment Income of -$27000.0 for Q1 2022, down 150.94% quarter-over-quarter from $53000.0 in Q2 2010.
Powered by 
Analysis
Lexicon Pharmaceuticals (LXRX) Non Operating Investment Income (2010 - 2022) Analysis & Trends
Lexicon Pharmaceuticals (LXRX) has reported Non Operating Investment Income for 2 consecutive years, with -$27000.0 the latest figure, recorded in Q1 2022.
- In Q1 2022, Non Operating Investment Income changed N/A year-over-year to -$27000.0; the TTM figure through Mar 2022 stood at -$27000.0 (changed N/A YoY), while the FY2010 annual figure was $141000.0, down 87.98% from the prior year.
- Non Operating Investment Income eased to -$27000.0 in Q1 2022 per LXRX's latest filing, from $53000.0 in the prior quarter.
- Across five years, Non Operating Investment Income topped out at -$27000.0 in Q1 2022 and bottomed at -$27000.0 in Q1 2022.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Operating Investment Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | - |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | - |
| 10 | Lexicon Pharmaceuticals | 978.15 Mn | 787.54 Mn | 653,000.00 | - |